Servier completes the acquisition of MVA-member company Symphogen

    Symphogen becomes the antibody center of excellence within Servier strengthening the Group’s pipeline

    Yesterday, Servier announced that it has completed the acquisition of Symphogen A/S. Symphogen will now function as the antibody center of excellence of Servier in several different therapeutic areas including oncology. Symphogen, now a subsidiary of Servier, will keep its operational autonomy and continue to rely on its experienced employees while maintaining its headquarters in Ballerup, Denmark.

    As part of the acquisition, Christophe Thurieau, Executive Director of Servier Research Institute, has been appointed Chief Executive Officer of Symphogen and Karin Garre, former Chief Operating Officer of Symphogen, has been appointed General Manager of Symphogen. Martin Olin, former
    Chief Executive Officer of Symphogen, will act as an external consultant to support this transition.

    “The completion of this transaction marks a very exciting journey for Symphogen and Servier. Anchored in a pre-existing strategic collaboration, this acquisition supports the R&D strategy of Servier within antibodies thanks to the capabilities of Symphogen. As the two organizations share key values, I believe this unification is positioned for a great outcome going forward.” says Karin Garre, General Manager of Symphogen.

    Read full press release here